Skip to content

usefulness of cold snare polypectomy for patients taking novel oral anticoagulant and warfarin

usefulness of cold snare polypectomy for patients taking novel oral anticoagulant and warfarin - usefulness of cold snare polypectomy for patients taking novel oral anticoagulant and warfarin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020106
Enrollment
60
Registered
2015-12-07
Start date
2015-12-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal polyp

Interventions

To perform cold snare polypectomy for colorectal polyps in patients taking NOAC. To perform cold snare polypectomy for colorectal polyps in patients taking warfarin.

Sponsors

Yokohama CIty University School of Medicine Department of Gastroenterology and Hepatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.patients with colorectal polyps who are going to receive endoscopic resection. 2.the polyp is no larger than 10mm, not suspected of high grade or early cancer, and not Ip in morphology. 3.patietns who are taking NOAC or warfarin. 4.NOAC includes dabigatran, rivaroxaban , apixaban, and edoxaban.

Exclusion criteria

Exclusion criteria: 1.combination use of antiplatelet agents. 2.history of inflammatory bowel disease. 3.Patients with severe heart failure, renal failure, psychiatric disorder, liver failure. 4.pregnancy

Design outcomes

Primary

MeasureTime frame
late bleeding(within 2 weeks after procedure)

Secondary

MeasureTime frame
early bleeding; adverse events other than bleeding; rate of complete resection

Countries

Japan

Contacts

Public ContactTakuma Higurashi

Yokohama City University School of Medicine Department of Gastroenterology and Hepatorogy

takuma_h@yokohama-cu.ac.jp045-787-2640

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026